Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Behind Lilly's decline ...

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the ...

Type 1 diabetes is a lifelong condition in which the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. The loss of these cells leads to high blood sugar ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.